Huagongshe화공사 화학 정보 인쇄 보고서 · 연구 참고용
2-(propan-2-yl)-1H-1,3-benzodiazole → 2-(4-((2-(2-isopropyl-1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8-yl)methyl)piperazin-1-yl)-2-methylpropan-1-ol
참여 물질
| 역할 | 이름 | HCID | 투입량 |
|---|---|---|---|
| 반응물 | 2-(propan-2-yl)-1H-1,3-benzodiazole | HCID 22121 | — |
| 반응물 | 2-(4-((2-chloro-9-methyl-6-morpholino-9H-purin-8-yl)methyl)piperazin-1-yl)-2-methylpropan-1-ol | HCID 86648251 | — |
| 생성물 | 2-(4-((2-(2-isopropyl-1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8-yl)methyl)piperazin-1-yl)-2-methylpropan-1-ol | HCID 59605300 | — |
반응 단계
2-(4-((2-Chloro-9-methyl-6-morpholino-9H-purin-8-yl)methyl)piperazin-1-yl)-2-methylpropan-1-ol (70 mg) was reacted with 2-isopropylbenzimidazole via General Procedure I for Buchwald coupling to give 28 mg 476 following reverse phase purification. MS (Q1) 548.3 (M)+
출처 및 근거
| DOI | 10.6084/m9.figshare.5104873.v1 |
|---|---|
| 특허 번호 | US08173650B2 |
| 출처 데이터셋 | uspto-grants-2012_05 |
| ORD ID | ord-fd84d591836440b9b8d5b7951b99fbba |
| 출처 메모 | uspto-grants-2012_05 |